​

Black Diamond Therapeutics (BDTX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

BDTX Stock Forecast

Black Diamond Therapeutics (BDTX) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $8.00, with a high of $8.00 and a low of $8.00. This represents a 196.30% increase from the last price of $2.70.

$2 $3 $4 $5 $6 $7 $8 High: $8 Avg: $8 Low: $8 Last Closed Price: $2.7

BDTX Stock Rating

Black Diamond Therapeutics stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (90.91%), 1 Hold (9.09%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 1 10 Strong Sell Sell Hold Buy Strong Buy

BDTX Price Target Upside V Benchmarks

TypeNameUpside
StockBlack Diamond Therapeutics196.30%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts--3
Avg Price Target--$8.00
Last Closing Price$2.70$2.70$2.70
Upside/Downside--196.30%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 26261--9
Mar, 26261--9
Feb, 26261--9
Jan, 26261--9
Dec, 2527---9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 16, 2026Kelsey GoodwinPiper Sandler$8.00$2.67199.63%196.30%
Oct 15, 2025Laura PrendergastStifel Nicolaus$8.00$4.1493.24%196.30%
Sep 03, 2025Brad CaninoGuggenheim$8.00$2.88177.78%196.30%
Jul 31, 2024Laura PrendergastRaymond James$20.00$5.91238.41%640.74%
Jun 03, 2024Joseph CalanzaroPiper Sandler$12.00$4.78151.05%344.44%
May 16, 2024Robert BurnsH.C. Wainwright$11.00$5.44102.21%307.41%
Apr 08, 2024Robert DriscollWedbush$16.00$5.06216.21%492.59%
Mar 18, 2024Raghuram SelvarajuH.C. Wainwright$12.00$4.70155.32%344.44%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Apr 29, 2026H.C. WainwrightBuyBuyhold
Jan 16, 2026Piper SandlerOverweightOverweighthold
Dec 03, 2025GuggenheimBuyNeutraldowngrade
Sep 03, 2025GuggenheimBuyinitialise
Sep 23, 2024Cowen & Co.BuyBuyhold
Sep 18, 2024H.C. WainwrightBuyBuyhold
Sep 10, 2024Piper SandlerOverweightOverweighthold
Jul 30, 2024Raymond JamesOutperforminitialise
Jun 03, 2024Piper SandlerOverweightOverweighthold
May 16, 2024H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$-4 $-3 $-2 $-1 $0 $1 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.88$-1.27$0.39---
Avg Forecast$-1.98$-1.30$-1.22$-1.51$-1.73$-1.12
High Forecast$-1.95$-1.24$-0.82$-0.77$-0.72$-1.12
Low Forecast$-2.02$-1.34$-1.93$-2.47$-3.11$-1.12
Surprise %-5.05%-2.31%-131.97%---

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast--$438.00K$3.89M$14.87M$107.50M
High Forecast--$438.00K$3.89M$14.87M$107.50M
Low Forecast--$438.00K$3.89M$14.87M$107.50M
Surprise %------

Net Income Forecast

$-150M $-110M $-70M $-30M $10M $50M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-82.44M$-69.68M$22.37M---
Avg Forecast$-87.43M$-56.70M$-81.55M$-71.21M$-84.22M$-49.34M
High Forecast$-85.88M$-54.50M$-36.13M$-33.85M$-31.66M$-49.34M
Low Forecast$-88.97M$-58.90M$-85.03M$-108.57M$-136.77M$-49.34M
Surprise %-5.70%22.88%-127.43%---

BDTX Forecast FAQ

Is Black Diamond Therapeutics stock a buy?

Black Diamond Therapeutics stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Black Diamond Therapeutics is a favorable investment for most analysts.

What is Black Diamond Therapeutics's price target?

Black Diamond Therapeutics's price target, set by 11 Wall Street analysts, averages $8 over the next 12 months. The price target range spans from $8 at the low end to $8 at the high end, suggesting a potential 196.30% change from the previous closing price of $2.7.

How does Black Diamond Therapeutics stock forecast compare to its benchmarks?

Black Diamond Therapeutics's stock forecast shows a 196.30% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Black Diamond Therapeutics over the past three months?

  • April 2026: 22.22% Strong Buy, 66.67% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • March 2026: 22.22% Strong Buy, 66.67% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 22.22% Strong Buy, 66.67% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.

What is Black Diamond Therapeutics’s EPS forecast?

Black Diamond Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-1.51, marking a -487.18% decrease from the reported $0.39 in 2025. Estimates for the following years are $-1.73 in 2027, and $-1.12 in 2028.

What is Black Diamond Therapeutics’s revenue forecast?

Black Diamond Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $3.89M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $14.87M, and $107.5M for 2028.

What is Black Diamond Therapeutics’s net income forecast?

Black Diamond Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-71.207M, representing a -418.36% decrease from the reported $22.37M in 2025. Projections indicate $-84.216M in 2027, and $-49.341M in 2028.